Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CombiMatrix nets $11.2mm through public offering of preferred shares

Executive Summary

CombiMatrix Corp. (cytogenomic testing for prenatal diagnosis, miscarriage, and pediatric developmental disorders) netted $11.2mm through the public sale of 12k units at $1k apiece. Each unit consisted of one Series D preferred share (convertible into 485.4369 common shares at $2.06) and a five-year warrant to purchase 485.4369 common at $3.12. CombiMatrix' stock averaged $2.80 at the time of the sale.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies